Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received a drug registration certificate for Angong Niuhuang Pills from the Vietnamese Ministry of Health, which will allow its subsidiary to expand its market presence in Vietnam [1][3]. Group 1: Drug Information - The drug Angong Niuhuang Pills is a prescription traditional Chinese medicine used for clearing heat and detoxifying, as well as calming and opening the orifices [2]. - The registration number for Angong Niuhuang Pills is VNCT-00006-25, and it is manufactured by Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. [1]. Group 2: Financial Performance - In 2024, the sales revenue of Angong Niuhuang Pills in China reached RMB 498,242 million, while the sales revenue for Zhongyi Pharmaceutical was RMB 15,611.83 million [2]. - The total research and development investment for the Angong Niuhuang Pills project by Zhongyi Pharmaceutical has reached approximately RMB 3,279.81 million (unaudited) [2]. Group 3: Market Impact - The registration of Angong Niuhuang Pills is expected to enhance the market competitiveness of the company’s products and facilitate the expansion of its business in Vietnam [3]. - The impact of this registration on the company's current performance is not expected to be significant [3].

Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

资本运作持续发力，广药资本在管基金认缴规模47亿元，实缴24亿元，将重点投向创新药、高端医疗器械等前沿领域；科 技创新强化核心引擎，布局近20项在研新药，今年新增26个新产品项目；国际拓展迈入新阶段，持续开拓东南亚、中东、南美 市场。 作为本次研讨会的核心亮点之一，广药集团正式揭晓核医疗产业布局及广州白云山稀核健康医药有限公司创新成果。与此 同时，白云山稀核健康与全球医疗科技巨头GE医疗签署战略合作协议，以跨界协同赋能核医疗产业高质量发展。 广药集团党委书记、董事长李小军在欢迎辞中表示，广药集团长期稳健发展与产业链上下游伙伴的精诚协作密不可分。当 前，面对医药健康行业新变化，广药集团正锚定"现代化、数字化、科技化、国际化"战略方向，全力推进"十五五"规划，向 着"再造一个新广药"的目标加速迈进，并取得多方面进展。 （编辑 李家琪 郭之宸） 会上，广药集团联合国家药监局南方医药经济研究所共同发起的"中国创新药研发与产业发展研究报告项目"正式启动。这 一举措将有效整合产业链上下游资源，推动破解创新药研发"卡脖子"难题，助力我国从制药大国向制药强国跨越。 本报讯 （记者王镜茹）11月18日，2025年广州医药集团有 ...

Investment Rating - The report does not explicitly provide an investment rating for the erectile dysfunction (ED) drug industry in China [1]. Core Insights - The Chinese ED drug market is experiencing strong demand and continuous growth, with a shift from traditional medical needs to broader sexual function enhancement [21]. - The market is characterized by increasing competition from domestic generic drugs and new drug developments, which are expected to intensify in the future [21]. - The leading products in the market, such as Sildenafil (Viagra) and Tadalafil (Cialis), have established strong brand recognition and market presence, making it challenging for new entrants to compete [16]. Summary by Sections Current Competitive Landscape - The competitive landscape of the Chinese ED drug market includes several key players with established products such as Sildenafil, Tadalafil, and others, with varying market entry dates and approval statuses [2]. - As of August 2025, the number of approved drug applications and suppliers for various ED drugs is as follows: Sildenafil (92 approvals, 53 suppliers), Tadalafil (172 approvals, 81 suppliers), and others [2]. Differentiation of New Drugs - New drugs like Sumenafil and Tonafadil are positioned with unique advantages, including lower effective doses, safety profiles, and potential for treating pulmonary arterial hypertension [7][9]. - Sumenafils' clinical trials indicate a lower incidence of adverse reactions compared to existing drugs, enhancing its market appeal [9]. Research Progress of PDE5 Inhibitors - The report highlights the ongoing research and development of PDE5 inhibitors, noting that the market is exploring new structural variants and indications beyond traditional uses [11]. - Traditional Chinese medicine is also recognized for its historical role in treating ED, with various herbal ingredients showing PDE5 inhibitory activity [11]. Market Demand and Future Trends - The demand for ED drugs is driven by both medical needs and psychological factors, with a growing acceptance of sexual health discussions in society [21]. - The market is expected to see an increase in competition from domestic companies entering through generics and innovative formulations, leading to a more dynamic market environment [21].

本次获得越南卫生部传统药品管理局颁发的安宫牛黄丸药品注册证书后，该药品将由中一药业授权 TNHH NEWSEEN COAST公司在越南地区销售，有助于中一药业扩展越南市场业务，提升本公司产品 市场竞争力。本次获得安宫牛黄丸药品注册证书，对公司当期业绩无重大影响。 智通财经APP讯，白云山(00874)公布，近日，公司全资子公司广州白云山中一药业有限公司(以下简 称"中一药业")收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 该信息由智通财经网提供 ...

中一药业于2024年6月20日向越南卫生部传统药品管理局递交了安宫牛黄丸(Angong Niuhuang Pills)药品 注册申请。安宫牛黄丸的功能主治为清热解毒，镇惊开窍。本次获得越南卫生部传统药品管理局颁发的 安宫牛黄丸药品注册证书后，该药品将由中一药业授权TNHH NEWSEEN COAST公司在越南地区销 售，有助于中一药业扩展越南市场业务，提升公司产品市场竞争力。 格隆汇11月19日丨白云山(00874.HK)发布公告，近日，公司全资子公司广州白云山中一药业有限公司 (以下简称"中一药业")收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 ...

本次获得越南卫生部传统药品管理局颁发的安宫牛黄丸药品注册证书后，该药品将由中一药业授权 TNHH NEWSEEN COAST公司在越南地区销售，有助于中一药业扩展越南市场业务，提升本公司产品 市场竞争力。本次获得安宫牛黄丸药品注册证书，对公司当期业绩无重大影响。 白云山(00874)公布，近日，公司全资子公司广州白云山中一药业有限公司(以下简称"中一药业")收到越 南卫生部传统药品管理局签发的安宫牛黄丸注册证书。 ...

北京商报讯（记者 王寅浩 宋雨盈）11月19日，白云山发布公告称，公司全资子公司广州白云山中一药 业有限公司收到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书，类别为处方中成药。根据公 告，安宫牛黄丸的功能主治为清热解毒，镇惊开窍。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司收到越南藥品註冊證書的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月19日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025－079 广州白云山医药集团股份有限公司 关于子公司收到越南药品注册证书的公告 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 注册持有人：TNHH NEWSEEN COAST 制造商：广州白云山中一药业有限公司 二、药品的其他相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记 ...

剂型：丸剂 类别：处方中成药 注册编号：VNCT-00006-25 注册持有人：TNHH NEWSEEN COAST 制造商：广州白云山中一药业有限公司 证券代码：600332 证券简称：白云山 公告编号：2025－079 广州白云山医药集团股份有限公司 关于子公司收到越南药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 全资子公司广州白云山中一药业有限公司（以下简称"中一药业"）收 到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。现将相关情 况公告如下： 一、药品的基本情况 名称：安宫牛黄丸（Angong Niuhuang Pills） 根据米内网数据显示，2024年安宫牛黄丸在中国城市、县级公立医 院和城市、网上药店的销售额为人民币498,242万元。2024年中一药业安 1 宫牛黄丸的销售收入为人民币15,611.83万元。 截至本公告日，中一药业在安宫牛黄丸药品研发项目上已累计投入 研发费用合计约人民币3,279.81万元（未审计）。 三 ...